


PHARMACEUTICAL 2023



Minerva Neurosciences Inc. Rank 360 of 446





PHARMACEUTICAL 2023



Minerva Neurosciences Inc. Rank 360 of 446

The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 255% points.

The company's Economic Capital Ratio, given in the ranking table, is -102%, being 145% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	40,159
Cost of Goods Sold	0
Intangible Assets	14,869
Liabilities, Current	1,378
Liabilities, Non-Current	0
Other Assets	43
Other Compr. Net Income	0
Other Expenses	7,407
Other Liabilities	73,734
Other Net Income	529
Other Revenues	0
Property and Equipment	16
Research and Development	14,649
Selling, General and Administrative Expense	10,582

Output Variable	Value in 1000 USD
Assets	55,087
Liabilities	75,111
Expenses	32,638
Revenues	0
Stockholders Equity	-20,024
Net Income	-32,109
Comprehensive Net Income	-32,109
Economic Capital Ratio	-102%

